Sung Ok Hong1, Chae-Yoon Lee2, Junho Jung3, Deog-Yoon Kim4, Christian Walter3, Yong-Dae Kwon5. 1. Department of Dentistry (Oral & Maxillofacial Surgery), International St. Mary's Hospital, Catholic Kwandong University, Incheon, South Korea. 2. Department of Oral & Maxillofacial Surgery, Graduate School, Kyung Hee University, Kyungheedaero 26, Seoul, 02447, South Korea. 3. Department of Oral & Maxillofacial Surgery, Universitätsmedizin Mainz, Augustusplatz 2, Mainz, 55131, Germany. 4. Department of Nuclear Medicine, School of Medicine, Kyung Hee University, Kyungheedaero 26, Seoul, 02447, South Korea. 5. Department of Oral & Maxillofacial Surgery, Center for Refractory Jawbone Diseases, School of Dentistry, Kyung Hee University, Kyungheedaero 26, Seoul, 02447, South Korea. yongdae.kwon@gmail.com.
Abstract
OBJECTIVE: The objective of this study were to find the annual case trend of inflammatory jawbone diseases and to investigate the impact of medication-related osteonecrosis of the jaws (MRONJ). MATERIAL AND METHODS: A retrospective study of 372 patients diagnosed with inflammatory jawbone condition except for alveolar osteitis from 2007 to 2015 was initiated. History taking and investigation of etiologic factors MRONJ, osteoradionecrosis (ORN), odontogenic infection, foreign body, and trauma were investigated. A separate analysis showed the number of MRONJ cases in two age groups (under 70 years; 70 years and over) and serum C-terminal peptide (s-CTX) values that were found. RESULTS: The results showed that the number of MRONJ cases was significantly larger in the older age group (p < 0.05). Regarding gender and sites of lesions, MRONJ was significantly frequent in the female and the mandible (p < 0.05). The R 2 values for the regression analysis for MRONJ (R 2 = 0.9234) and odontogenic etiology (R 2 = 0.0427) signified linear increase in the number of MRONJ cases, whereas bone lesions due to traditional odontogenic etiology stayed stationary. CONCLUSION: The number of MRONJ has escalated, and most of the patients are elderly people. The current trend of inflammatory conditions of the jaw may have changed since the advent of MRONJ. CLINICAL RELEVANCE: Long-term bisphosphonate therapy became a major risk factor for the osteomyelitis and osteonecrosis of the jaws. Thorough medical history, taking would be essential and communication with prescribing physicians should be emphasized during the dental treatment planning.
OBJECTIVE: The objective of this study were to find the annual case trend of inflammatory jawbone diseases and to investigate the impact of medication-related osteonecrosis of the jaws (MRONJ). MATERIAL AND METHODS: A retrospective study of 372 patients diagnosed with inflammatory jawbone condition except for alveolar osteitis from 2007 to 2015 was initiated. History taking and investigation of etiologic factors MRONJ, osteoradionecrosis (ORN), odontogenic infection, foreign body, and trauma were investigated. A separate analysis showed the number of MRONJ cases in two age groups (under 70 years; 70 years and over) and serum C-terminal peptide (s-CTX) values that were found. RESULTS: The results showed that the number of MRONJ cases was significantly larger in the older age group (p < 0.05). Regarding gender and sites of lesions, MRONJ was significantly frequent in the female and the mandible (p < 0.05). The R 2 values for the regression analysis for MRONJ (R 2 = 0.9234) and odontogenic etiology (R 2 = 0.0427) signified linear increase in the number of MRONJ cases, whereas bone lesions due to traditional odontogenic etiology stayed stationary. CONCLUSION: The number of MRONJ has escalated, and most of the patients are elderly people. The current trend of inflammatory conditions of the jaw may have changed since the advent of MRONJ. CLINICAL RELEVANCE: Long-term bisphosphonate therapy became a major risk factor for the osteomyelitis and osteonecrosis of the jaws. Thorough medical history, taking would be essential and communication with prescribing physicians should be emphasized during the dental treatment planning.
Authors: M A Dimopoulos; E Kastritis; C Bamia; I Melakopoulos; D Gika; M Roussou; M Migkou; E Eleftherakis-Papaiakovou; D Christoulas; E Terpos; A Bamias Journal: Ann Oncol Date: 2008-08-09 Impact factor: 32.976
Authors: C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi Journal: Ann Oncol Date: 2008-07-22 Impact factor: 32.976
Authors: Matthew Tamplen; Tristan Fowler; Jeffery Markey; P Daniel Knott; Larry J Suva; Tamara Alliston Journal: Head Neck Date: 2018-03-09 Impact factor: 3.147
Authors: L Dos Santos Ferreira; L G Abreu; C B Calderipe; M D Martins; L F Schuch; A C U Vasconcelos Journal: Osteoporos Int Date: 2021-07-31 Impact factor: 4.507